Download Congestive Heart Failure: Major World Markets, Volume I: Pharmaceutical Management Brochure

Brochure
More information from http://www.researchandmarkets.com/reports/2860786/
Congestive Heart Failure: Major World Markets, Volume I: Pharmaceutical
Management
Description:
Congestive heart failure is an increasingly important cause of cardiovascular morbidity and mortality. It is
the number one cause of hospitalization among individuals aged 65 and over. The United States Medicare
system pays out more for the care of congestive heart failure than it does for all forms of cancer combined.
While this is a challenge for the US healthcare system, it indicates a strong market opportunity for
pharmaceutical companies involved in CHF treatment.
Kalorama Information's Congestive Heart Failure, Major World Markets series looks at CHF treatment.
Volume I of this series looks at Pharmaceutical Treatments in the following key categories which are used to
treat this disease:
ACEIs/ARBs
Beta-Blockers
Diuretics
Inotropes
Vasodilators
Aldosterone Inhibitors
This report includes current market, market forecasts, product discussion and pipeline analysis are included
for each segement of this report. General trends in this important disease category are also included.
Relevant companies in the industry are profiled. This report is the result of Dr. Kenneth Krul's exhaustive
analysis and primary research with key executives in the industry.
Abbott Laboratories
Actelion Pharmaceuticals US
Aldagen
Alexion Pharmaceuticals
AstraZeneca LP
Bayer Healthcare Pharmaceuticals
(Bayer Schering Pharma)
Bristol-Myers Squibb
CardioVascular Biotherapeutics
CoGenesys, Inc.
Encysive Pharmaceuticals
GlaxoSmithKline (US)
Inotek Pharmaceuticals
Mylan Pharmaceuticals
Novartis Pharmaceutical Corp.
Pfizer, Inc.
Roche Pharmaceuticals
Sanofi-Aventis (US)
Scios, Inc.
Vasogen, Inc.
Zealand Pharma
Contents:
TABLE OF CONTENTS
CHAPTER ONE: EXECUTIVE SUMMARY
Background
Scope and Methodology
Size and Growth of Market
Market Trends
The Nature of the Industry
The New Technologies
CHAPTER TWO: INTRODUCTION
Background
Pathophysiology
Types of Heart Failure
Left Ventricular (LV) Failure
Right Ventricular (RV) Failure
Systolic Dysfunction
Diastolic Dysfunction
High Output Failure
Theories of Congestive Heart Failure
Hemodynamic Response Theory
Neurohormonal Response Theory
Renal Response Theory
Conditions Leading to Congestive Heart Failure
Myocardial Infarction
Hypertension
Cardiomyopathy
Atrial Fibrillation
Other Risk Factors
Diagnosis of Congestive Heart Failure
Classification of Congestive Heart Failure Patients
Epidemiology
United States
Europe
Japan
CHAPTER THREE:TREATMENT OF CONGESTIVE HEART FAILURE
Pharmacological Therapy
Overview
Standard Pharmacological Therapy
ACE Inhibitors and Related Drugs
Angiotensin II Receptor Inhibitors (ARBs)
â-Blockers
Diuretics
Positive Inotropic Agents
Vasodilators
Aldosterone Blockers
Limitations of Pharmaceuticals
Emerging Drugs to Treat Congestive Heart Failure
CHAPTER FOUR: CONGESTIVE HEART FAILURE PATIENT
MANAGEMENT
Guidelines for Management of Chronic Heart Failure
Strategies to Maintain Quality Patient Care and Con`tain Costs
Patient Education Programs
Dedicated Multidisciplinary Congestive Heart Failure Clinics
CHAPTER FIVE: THE MARKET FOR CHF PHARMACEUTICALS
Market Analysis
United States
Europe
Japan
CHAPTER SIX: COMPANY PROFILES
Abbott Laboratories
Actelion Pharmaceuticals US
Aldagen
Alexion Pharmaceuticals
AstraZeneca LP
Bayer Healthcare Pharmaceuticals (Bayer Schering Pharma)
Bristol-Myers Squibb
CardioVascular Biotherapeutics
CoGenesys, Inc.
Encysive Pharmaceuticals
GlaxoSmithKline (US)
Inotek Pharmaceuticals
Mylan Pharmaceuticals
Novartis Pharmaceutical Corp.
Pfizer, Inc.
Roche Pharmaceuticals
Sanofi-Aventis (US)
Scios, Inc.
Vasogen, Inc.
Zealand Pharma
CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS
First Conclusion
Second Conclusion
Third Conclusion
Fourth Conclusion
Fifth Conclusion
Sixth Conclusion
Seventh Conclusion
Eighth Conclusion
APPENDIX A: GLOSSARY
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Figure 1-1: Incidence of Congestive Heart Failure Cases in the Major World
Healthcare Markets: 2007 - 2017
Figure 1-2: Prevalence of Congestive Heart Failure Cases in the Major World
Healthcare Markets: 2007 - 2017
Table 1-1: Estimated Market Sizes for CHF Pharmaceuticals in the Major World
Healthcare Markets: 2007 - 2017 (US$ Billions)
Figure 1-3: Market Potential Trending and Composition for Congestive Heart
Failure Therapeutics in the World’s Major Therapy Markets:2007 - 2017
Figure 1-4: Composition of the Markets for Congestive Heart Failure Therapeutics
by Product Classification: 2007 - 2017
Table 1-3: Examples of Companies Competitive in Congestive Heart Failure
Therapeutics
CHAPTER TWO: INTRODUCTION
Table 2-1: International Cardiovascular Disease (CVD) Statistics
Table 2-2: United States CHF Statistics: 2004
Table 2-3: CHF Data Sources
Table 2-4: Common Contributors to Congestive Heart Failure
Figure 2-1: Incidence and Prevalence of Congestive Heart Failure In the
World’s Major Healthcare Markets: 2007 - 2017
Figure 2-2: Incidence Rates of Congestive Heart Failure in the
Major World Healthcare Markets: 200l - 2017
Figure 2-3: Prevalence Rates of Congestive Heart Failure in the
Major World Healthcare Markets: 2007 - 2017
Figure 2-4: Percentage Breakdown of Deaths from Cardiovascular
Diseases: 2003
Table 2-5: Incidence and Prevalence of CHF in the
United States: 2007 - 2017
Figure 2-5: Incidence and Prevalence of CHF in the United States: 2007 - 2017
Figure 2-6: The Distribution of Congestive Heart Failure In the Five
Major European Healthcare Markets: 2007
Table 2-6: Incidence and Prevalence of CHF in the Major Healthcare
Markets of Europe: 2007 - 2017 (Thousands)
Figure 2-7: Incidence and Prevalence of CHF in the Major Healthcare
Markets of Europe: 2007 - 20017 (Thousands)
Table 2-7: Incidence and Prevalence of CHF in Japan: 2007 - 2017
Figure 2-8: Incidence and Prevalence of CHF in Japan: 2007 - 20017
CHAPTER THREE: TREATMENT OF CONGESTIVE HEART FAILURE
Table 3-1: Therapeutic Strategies for Symptomatic Congestive Heart Failure
Table 3-2: Pharmacological Response to the Pathophysiology of
Cardiac Performance
Table 3-3: Common ACE Inhibitors Recommended for the Treatment of CHF
Table 3-4: Common Angiotensin II Receptor Antagonists Recommended
for the Treatment of CHF
Table 3-5: Common â-Receptor Antagonists Recommended for the
Treatment of CHF
Table 3-6: Common Diuretics Recommended for the Treatment of CHF
Table 3-7: Common Inotropic Drugs Available for the Treatment of CHF
Table 3-8: Common Vasodilators Available for the Treatment of CHF
Table 3-9: Common Aldosterone Blocking Drugs Recommended for
the Treatment of CHF
Table 3-10: New Drugs in Development for the Treatment of CHF
CHAPTER FOUR: CONGESTIVE HEART FAILURE PATIENT
MANAGEMENT
Figure 4-1: ACC/AHA Guideline Summary for Recommended Therapy of
Congestive Heart Failure by Stage of the Disease
Table 4-1: ACC/AHA Staging of Congestive Heart Failure
Table 4-2: 2005 ACC/AHA Guidelines for Evaluation and Therapy
for Congestive Heart Failure
CHAPTER FIVE: THE MARKET FOR CHF PHARMACEUTICALS
Table 5-1: Estimated Market Potential for CHF Pharmaceuticals in the Major
World Healthcare Markets: 2007 - 2017
Figure 5-1: Trending in the Estimated Market Potential for CHF Pharmaceuticals in
the Major World Healthcare Markets: 2007 - 2017
Figure 5-2: Distribution of the Estimated Market Potential for CHF Pharmaceuticals
in the Major World Healthcare Markets: 2007 - 2017
Table 5-2: Estimated Market Potential for CHF Pharmaceuticals in the
United States: 2007 - 2017 ($Billions)
Figure 5-3: Trending in the Estimated Market Potential for CHF Pharmaceuticals in
the United States: 2007 - 2017
Figure 5-4: Distribution of the Estimated Market Potential by Segments for CHF
Pharmaceuticals in the United States: 2007 - 2017
Table 5-3: Estimated Market Potential for CHF Pharmaceuticals in the Major European
Markets: 2007 - 2017
Figure 5-5: Trending in the Estimated Market Potential for CHF Pharmaceuticals
in the Major European Markets: 2007 - 2017
Figure 5-6: Distribution of the Estimated Market Potential by Segments for CHF
Pharmaceuticals in the Major European Markets: 2007 - 2017
Table 5-4: Estimated Market Potential for CHF Pharmaceuticals in the
Japanese Market: 2007 - 2017
Figure 5-7: Trending in the Estimated Market Potential for CHF Pharmaceuticals in
the Japanese Market: 2007 - 2017
Figure 5-8: Distribution of the Estimated Market Potential by Segments for
CHF Pharmaceuticals in the Japanese Market: 2007 - 2017
Ordering:
Order Online - http://www.researchandmarkets.com/reports/2860786/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from
USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Name:
Congestive Heart Failure: Major World Markets, Volume I: Pharmaceutical
Management
Web Address:
http://www.researchandmarkets.com/reports/2860786/
Office Code:
SCHL3FA7
Product Formats
Please select the product formats and quantity you require:
Quantity
Electronic (PDF) Single User:
USD 895
Hard Copy:
USD 3895 + USD 58 Shipping/Handling
Electronic (PDF) Enterprisewide:
USD 6990
* Shipping/Handling is only charged once per order.
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title:
First Name:
Mr
Mrs
Dr
Miss
Last Name:
Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Ms
Prof
Page 1 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card:
You will receive an email with a link to a secure webpage to enter your
credit card details.
Pay by check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.
Pay by wire transfer:
Please transfer funds to:
Account number
833 130 83
Sort code
98-53-30
Swift code
ULSBIE2D
IBAN number
IE78ULSB98533083313083
Bank Address
Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
http://www.researchandmarkets.com/info/terms.asp
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World